NeoGenomics, Inc. (NASDAQ:NEO) Director Steven C. Jones sold 10,426 shares of NeoGenomics stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $36.13, for a total value of $376,691.38. Following the completion of the sale, the director now owns 197,932 shares in the company, valued at approximately $7,151,283.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
NASDAQ NEO opened at $36.35 on Friday. NeoGenomics, Inc. has a 1-year low of $18.52 and a 1-year high of $41.03. The company has a market capitalization of $4.08 billion, a P/E ratio of 1,231.33 and a beta of 0.80. The business has a 50 day moving average price of $38.32 and a 200 day moving average price of $31.11. The company has a debt-to-equity ratio of 0.32, a current ratio of 6.79 and a quick ratio of 6.44.
NeoGenomics (NASDAQ:NEO) last announced its earnings results on Tuesday, July 28th. The medical research company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.06. The firm had revenue of $86.90 million for the quarter, compared to analysts’ expectations of $86.55 million. NeoGenomics had a positive return on equity of 0.73% and a negative net margin of 1.33%. NeoGenomics’s quarterly revenue was down 14.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.07 EPS. On average, research analysts expect that NeoGenomics, Inc. will post -0.01 earnings per share for the current fiscal year.
A number of equities research analysts have commented on NEO shares. Guggenheim started coverage on NeoGenomics in a research report on Friday, August 28th. They issued a “buy” rating and a $46.00 target price on the stock. CIBC downgraded NeoGenomics to a “neutral” rating and cut their price objective for the company from $11.00 to $9.00 in a report on Friday, May 15th. Zacks Investment Research downgraded NeoGenomics from a “strong-buy” rating to a “hold” rating in a report on Friday, August 7th. BidaskClub downgraded NeoGenomics from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 5th. Finally, Benchmark boosted their price objective on NeoGenomics from $35.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Three equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $37.50.
NeoGenomics Company Profile
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.
Recommended Story: P/E Growth (PEG)
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.